Fast Delivery High Purity Diabetes Treatment Fenofibrate CAS 49562-28-9

Fenofibrate is a lipid-lowering drug. The main mechanism of action is to inhibit HMG-CoA reductase and reduce the synthesis of cholesterol in cells, thereby reducing blood lipids.

Fenofibrate is suitable for the treatment of endogenous hypertriglyceridemia and primary hypercholesterolemia. It has been widely used in the United States, France, Japan and other countries, and has now become the drug of choice for the treatment of hyperlipidemia.

Fenofibrate is significantly better than statins in lowering TG and raising HDL-C. Because simple dyslipidemia is rare in diabetic patients, its common blood lipid profile is increased TC, decreased HDL-C, and low-density lipoprotein. -Cholesterol (LDL-C) is elevated or normal. Therefore, fenofibrate has a significant clinical effect in the treatment of lipid abnormalities in diabetic patients.

The latest research shows that fenofibrate also has anti-tumor effects. Fenofibrate can inhibit tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) factor monocytes through PPAR-α receptors. Cell expression, and promote tumor cell differentiation and apoptosis.